NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04887298,Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases,https://clinicaltrials.gov/study/NCT04887298,,COMPLETED,"This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.",NO,"Sarcoma,Soft Tissue|Pulmonary Metastasis",DRUG: Liposomal Annamycin (L-Annamycin),"Dose Limiting Toxicity, Number of patients with a dose limiting toxicity (DLT) at each dose evaluated, 21 days","Efficacy of L-Annamycin, Determine preliminary efficacy of L-Annamycin as per revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1), At the end of every other treatment cycle ( each cycle is 21 days)|Area Under the Plasma Concentration Versus Time Curve (AUC) of L-Annamycin, Determine pharmacokinetics of L-Annamycin and its metabolite, annamycinol as measured by AUC, Cycle 1 Day 1 ( each cycle is 21 days)",,"Moleculin Biotech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,36,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,MB-107,2021-06-05,2022-09-29,2024-08-06,2021-05-14,,2024-10-24,"Sarcoma Oncology Center, Santa Monica, California, 90403, United States|Washington University, Saint Louis, Missouri, 63110, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Ohio State University, Columbus, Ohio, 43210, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States",
